Erste Asset Management GmbH Acquires Shares of 42,000 BioNTech SE Sponsored ADR $BNTX

Key Points

• Erste Asset Management GmbH has purchased 42,000 shares of BioNTech SE Sponsored ADR, valued at approximately $3.99 million, marking a significant investment by the institutional investor.
• Several institutional investors, including T. Rowe Price Investment Management, have also recently increased their holdings or established new positions in BioNTech during the last quarter.
• BioNTech reported earnings of ($1.60) per share, which missed analyst expectations, despite revenue soaring by 102.6% year-over-year at $306.46 million.

Erste Asset Management GmbH purchased a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 42,000 shares of the company's stock, valued at approximately $3,988,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in BNTX. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech during the first quarter worth about $36,000. Costello Asset Management INC purchased a new stake in BioNTech in the 1st quarter valued at approximately $91,000. Goodman Advisory Group LLC purchased a new stake in BioNTech in the 1st quarter valued at approximately $105,000. Whittier Trust Co. boosted its holdings in BioNTech by 3,846.2% in the 1st quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock valued at $187,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in BioNTech by 61.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after purchasing an additional 713 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Trading Down 5.2%

Shares of NASDAQ BNTX traded down $5.81 during trading on Monday, hitting $105.07. 1,264,210 shares of the company traded hands, compared to its average volume of 928,315. The company has a 50-day moving average price of $109.90 and a 200-day moving average price of $105.38. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 1 year low of $81.20 and a 1 year high of $131.49. The firm has a market capitalization of $25.26 billion, a P/E ratio of -65.67 and a beta of 1.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. During the same period last year, the company posted ($3.36) earnings per share. The firm's revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Truist Financial reaffirmed a "buy" rating and issued a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Morgan Stanley lifted their price objective on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 10th. HC Wainwright lowered their price objective on BioNTech from $138.00 to $136.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Citigroup reaffirmed a "buy" rating and issued a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Finally, Wells Fargo & Company set a $150.00 price target on BioNTech and gave the stock an "overweight" rating in a research note on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and an average price target of $135.80.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.